Business Description
Nuo Therapeutics Inc
NAICS : 325414
SIC : 2836
ISIN : US67059V2097
Share Class Description:
AURX: Ordinary SharesTotal Employee Number:
10Description
Nuo Therapeutics Inc is a commercial-stage medical device company engaged in developing and marketing products for chronic wound care. The company operates as a single segment focused on regenerative therapies that utilize autologous (patient-derived) biological materials to promote natural healing. Its primary commercial product is the Aurix System, a point-of-care technology that produces platelet-rich plasma (PRP) therapy from a patient's own blood for use in the treatment of chronic wounds.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.24 | |||||
Equity-to-Asset | -0.71 | |||||
Debt-to-Equity | -0.8 | |||||
Debt-to-EBITDA | -0.54 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -18.27 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 185.8 | |||||
3-Year EBITDA Growth Rate | 13.4 | |||||
3-Year EPS without NRI Growth Rate | 15.9 | |||||
3-Year FCF Growth Rate | 36.6 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 61.19 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 61.25 | |||||
9-Day RSI | 56.1 | |||||
14-Day RSI | 51.1 | |||||
3-1 Month Momentum % | -33.96 | |||||
6-1 Month Momentum % | -42.38 | |||||
12-1 Month Momentum % | -41.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.11 | |||||
Quick Ratio | 0.93 | |||||
Cash Ratio | 0.19 | |||||
Days Inventory | 47.58 | |||||
Days Sales Outstanding | 47.45 | |||||
Days Payable | 117.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.8 | |||||
Shareholder Yield % | -0.65 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 65.46 | |||||
Operating Margin % | -53.67 | |||||
Net Margin % | -57.71 | |||||
EBITDA Margin % | -49.67 | |||||
FCF Margin % | -41.1 | |||||
OCF Margin % | -39.99 | |||||
ROA % | -144.91 | |||||
ROIC % | -264.68 | |||||
3-Year ROIIC % | 229.06 | |||||
ROC (Joel Greenblatt) % | -460.53 | |||||
ROCE % | -550.12 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 11.72 | |||||
EV-to-EBIT | -22.65 | |||||
EV-to-EBITDA | -24.47 | |||||
EV-to-Forward-EBITDA | 320.79 | |||||
EV-to-Revenue | 12.16 | |||||
EV-to-Forward-Revenue | 10.09 | |||||
EV-to-FCF | -29.57 | |||||
Earnings Yield (Greenblatt) % | -4.42 | |||||
FCF Yield % | -3.44 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:AURX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nuo Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 4.131 | ||
| EPS (TTM) ($) | -0.04 | ||
| Beta | -0.3138 | ||
| 3-Year Sharpe Ratio | 0.24 | ||
| 3-Year Sortino Ratio | 0.51 | ||
| Volatility % | 45.34 | ||
| 14-Day RSI | 51.1 | ||
| 14-Day ATR ($) | 0.033772 | ||
| 20-Day SMA ($) | 0.98166 | ||
| 12-1 Month Momentum % | -41.63 | ||
| 52-Week Range ($) | 0.8415 - 3.23 | ||
| Shares Outstanding (Mil) | 48.41 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nuo Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nuo Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-12-16 | In 145 days | ||
| Third quarter earnings results for 2026 | 2026-10-30 | In 98 days | ||
| Second quarter earnings results for 2026 | 2026-07-31 | In 7 days | ||
| First quarter earnings results for 2026 | 2026-05-21 | 1.15 (-2.74%) | ||
| Annual report for 2025 | 2026-03-30 | 1.44 (+10.77%) | ||
| General meeting for 2025 | 2025-12-16 | 2.15 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-10-30 | 2.29 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-07-31 | 1.63 (+0.00%) | ||
| First quarter earnings results for 2025 | 2025-04-30 | 1.37 (-14.38%) | ||
| Annual report for 2024 | 2025-04-01 | 1.20 (+0.00%) |
Show
Entries
Nuo Therapeutics Inc Frequently Asked Questions
What is Nuo Therapeutics Inc(AURX)'s stock price today?
The current price of AURX is $1.02. The 52 week high of AURX is $3.23 and 52 week low is $0.84.
When is next earnings date of Nuo Therapeutics Inc(AURX)?
The next earnings date of Nuo Therapeutics Inc(AURX) is 2026-07-31 Est..
Does Nuo Therapeutics Inc(AURX) pay dividends? If so, how much?
Nuo Therapeutics Inc(AURX) does not pay dividend.
Guru Commentaries on OTCPK:AURX
No articles.
Press Release
Articles on Nuo Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers